Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:

External device review pilot should await amendments to device law, NEMA says.

This article was originally published in The Gray Sheet

  • News

Executive Summary

THIRD-PARTY DEVICE REVIEW PROGRAM SHOULD LIMIT FDA ROLE TO OVERSIGHT, Robert Britain, head of the National Electrical Manufacturers Association's diagnostic imaging and therapy systems division said at a June 19 workshop in Rockville, Maryland. "Final approval authority for new products should rest with accredited third-party reviewers, rather than with FDA itself," Britain stated.

You may also be interested in...



Vemedia Acquires GSK Brands In Italy, Strikes Deal For GI Product In Spain

GSK has offloaded a further two brands, this time in Italy, giving Netherlands-based Vemedia the opportunity to bolster its portfolio in the country. Vemedia has also added to its offering in Spain by striking a separate deal with Puerto Galiano.

EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

Table

View full table

Tags:
UsernamePublicRestriction

Register

MT004280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By